Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 17/20 | 0.68 |
| ▸ | HRH2 | P25021 | 16/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.68 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7252832 | 0.91 | HRH1 (0.71) | HRH1HRH2HRH3KCNA5 | |
| SCHEMBL7252076 | 0.83 | HRH1 (0.70) | HRH1HRH2HRH3KCNA5 | |
| SCHEMBL14393458 | 0.83 | HRH3 (0.88) | HRH1HRH2HRH3 | |
| SCHEMBL7243576 | 0.82 | HRH2 (0.70) | HRH1HRH2KCNA5 | |
| SCHEMBL7251192 | 0.82 | HRH2 (0.59) | HRH1HRH2HRH3 | |
| SCHEMBL7244881 | 0.82 | HRH3 (0.62) | HRH1HRH2HRH3 | |
| Hydrochloric Acid SCHEMBL1714618 | 0.82 | HRH3 (0.86) | HRH1HRH2HRH3 | |
| SCHEMBL7242852 | 0.81 | HRH1 (0.70) | HRH1HRH2HRH3 | |
| SCHEMBL24324260 | 0.80 | HRH3 (0.73) | HRH1HRH2HRH3 | |
| SCHEMBL7244497 | 0.80 | HRH1 (0.60) | HRH1HRH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559140-B2 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBOTT LABORATORIES | 2003-05-06 | — | — | US | claimed |
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBVIE INC. | 2001-12-06 | — | — | US | claimed |
| WO-2001066534-A2 | CYCLIC AND BICYCLIC DIAMINO HISTAMINE-3 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2001-09-13 | — | — | WO | claimed |
| US-6559140-B2 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBOTT LABORATORIES | 2003-05-06 | — | — | US | disclosed |
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBVIE INC. | 2001-12-06 | — | — | US | disclosed |
| WO-2001066534-A2 | CYCLIC AND BICYCLIC DIAMINO HISTAMINE-3 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | HRH4, HRH2, HRH3 | HRH1 4/4885HRH2 2/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.